Four medical researchers at the forefront of developing treatments for depression present new findings in a special conference held at the Library's John W. Kluge Center. The program was part of the annual meeting of the Library of Congress Scholars Council. For transcript and more information, visit http://www.loc.gov/today/cyberlc/feature_wdesc.php?rec=7417
Views: 14002 LibraryOfCongress
D-Aspartic Acid (DAA) is a very popular supplement on the market. It is most well-known in gym locker rooms and on product labels for increasing testosterone levels and leading to muscle gain. In this quick video, I break down the current human data we have on DAA and explain why I don't recommend it to my athletes. For more information and updates head on over and like my Facebook page: https://www.facebook.com/DanGarnerNutritionSpecialist/
Views: 917 Coach Garner
People with diabetes cannot use food for energy the usual way because they do not have insulin, or insulin does not do its job correctly in their bodies. Insulin is a hormone made in the pancreas, which is an organ located behind the stomach. Insulin lowers blood glucose levels. People with diabetes may inject insulin with a syringe two or more times each day, usually before a meal or at bedtime.
Views: 316451 Children's Healthcare of Atlanta
Alzheimer's disease has emerged as the major health challenge of our generation. Against the backdrop of an aging population, brought about by meaningful advances in care for heart disease and cancer, Alzheimer's disease affects over 5 million Americans and is the only top cause of death with no therapy to stop or slow it. Biotechnology is the most promising weapon against this epidemic. We will discuss what we have learned from past clinical trials, and what to expect in the near future. Geoffrey A. Kerchner, MD, PhD, is Senior Medical Director at Genentech, Inc., and Adjunct Clinical Associate Professor of Neurology and Neurological Sciences at Stanford University School of Medicine. Geoffrey designs and oversees clinical trials of novel therapies for Alzheimer's disease and other neurodegenerative illnesses, while also maintaining an active clinical practice at an academic memory clinic. He is also on the Board of Directors of the Alzheimer's Association of Northern California and Northern Nevada. Geoffrey graduated from Harvard College and received his MD and PhD degrees from Washington University in St. Louis. Introduction by VP, Andrew Dahlkemper.
Views: 1225 Talks at Google